# Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19

> **NCT05007522** · PHASE3 · COMPLETED · sponsor: **Sen-Jam Pharmaceutical** · enrollment: 150 (actual)

## Conditions studied

- COVID-19 Respiratory Infection

## Interventions

- **DRUG:** Ketotifen/Indomethacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05007522
- **Lead sponsor:** Sen-Jam Pharmaceutical
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-03
- **Primary completion:** 2024-06-20
- **Final completion:** 2024-06-20
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2024-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05007522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05007522, "Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05007522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*